F. Dicker

发表

Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing

T. Haferlach, W. Kern, A. Stengel, 2018, Leukemia.

Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2011, Blood.

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Leukemia.

Landscape of TET2 mutations in acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Leukemia.

AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

A. Kohlmann, T. Haferlach, S. Schnittger, 2010, Leukemia.

Monoclonal B‐cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early‐stage CLL

T. Haferlach, S. Schnittger, W. Kern, 2012, British journal of haematology.

Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping

T. Haferlach, S. Schnittger, W. Kern, 2007, Leukemia.

Development and validation of a real-time quantification assay to detect and monitor BRAF V 600 E mutations in hairy cell leukemia

T. Haferlach, S. Schnittger, W. Kern, 2012 .

Correlation of flow cytometrically determined expression of ZAP‐70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2009, Cytometry. Part B, Clinical cytometry.

ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.

L. Rassenti, T. Kipps, A. Weiss, 2005, Blood.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

T. Haferlach, W. Kern, C. Haferlach, 2018, Blood advances.

Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference

T. Kipps, J. Reed, John Calvin Reed, 2006, Leukemia.

Phosphorylation-independent inhibition of parathyroid hormone receptor signaling by G protein-coupled receptor kinases.

M. Lohse, U. Quitterer, R. Winstel, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Dual regulation of the parathyroid hormone (PTH)/PTH-related peptide receptor signaling by protein kinase C and beta-arrestins.

M. Lohse, M. Castro, J. Vilardaga, 2002, Endocrinology.

A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1

M. Griesshammer, S. Schnittger, C. Haferlach, 2013, Leukemia.

Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2012, Cytometry. Part B, Clinical cytometry.

Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis

A. Kohlmann, T. Haferlach, S. Schnittger, 2010, Haematologica.

An Unusual Presentation of Cardiogenic Shock in the Emergency Department

Danielle McCollum, F. Dicker, 2017 .

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Leukemia.

Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B‐CLL) and its genetic characterization

T. Haferlach, S. Schnittger, W. Kern, 2014, British Journal of Haematology.

The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML

T. Haferlach, S. Schnittger, W. Kern, 2011, Leukemia.

Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T).

A. Kohlmann, T. Haferlach, S. Schnittger, 2009 .

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML

T. Haferlach, S. Schnittger, W. Kern, 2010, Genes, chromosomes & cancer.

Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).

T. Haferlach, W. Kern, R. Munker, 2009, Leukemia research.

Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.

T. Kipps, John Calvin Reed, R. Houghten, 2005, Blood.

Development of An Oligonucleotide Resequencing Array for Rapid Mutation Analysis in Acute Myeloid Leukemia with Normal Karyotype.

T. Haferlach, S. Schnittger, W. Kern, 2009 .

Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B‐cell neoplasms

T. Haferlach, S. Schnittger, W. Kern, 2010, British journal of haematology.

Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters

T. Haferlach, S. Schnittger, W. Kern, 2010, Genes, chromosomes & cancer.

Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2007, Cancer genetics and cytogenetics.

Short communication Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2007 .

Mutations of the TP53 Gene Occur in 13.4% of Acute Myeloid Leukemia and Are Strongly Associated with a Complex Aberrant Karyotype.

T. Haferlach, S. Schnittger, C. Schoch, 2006 .

Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy

T. Haferlach, S. Schnittger, W. Kern, 2008 .

Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells.

T. Kipps, A. Kater, T. Fukuda, 2005, Blood.

The role of different genetic subtypes of CEBPA mutated AML

C Haferlach, A Kohlmann, T Haferlach, 2014, Leukemia.

Digital imaging microscopy of firefly luciferase activity to directly monitor differences in cell transduction efficiencies between AdCMVLuc and Ad5LucRGD vectors having different cell binding properties.

S. Seeber, O. Mundigl, F. Dicker, 2001, Journal of virological methods.

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Haematologica.

Chronic Myeloproliferative Disorders

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative / myelodysplastic disorders : an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

UvA-DARE ( Digital Academic Repository ) Inhibitors of XIAP sensitize CD 40-activated chronic lymphocytic leukemia cells to CD 95-mediated apoptosis

J. Reed, C. Pinilla, K. Welsh, 2005 .

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Haematologica.

An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired

T. Haferlach, S. Schnittger, W. Kern, 2008 .

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.

T. Haferlach, J. Sundermann, S. Schnittger, 2011, Blood.

Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2007, Blood.

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

T. Haferlach, B. Falini, S. Schnittger, 2009, Blood.

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).

S. Ogawa, A. Kohlmann, T. Haferlach, 2012, Blood.

Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression.

T. Haferlach, S. Schnittger, C. Schoch, 2006, Blood.

Complex Aberrant Karyotypes and Unbalanced Translocations in CLL Correlate with an Unmutated IgVH Status: A Study on 133 Patients Studied with Chromosome Banding Analysis, Interphase FISH, IgVH Mutation Status, ZAP-70 RNA Expression and Immunophenotyping.

T. Haferlach, S. Schnittger, C. Schoch, 2005 .

Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia

T. Haferlach, S. Schnittger, W. Kern, 2015, British journal of haematology.

Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia

T. Haferlach, S. Schnittger, W. Kern, 2016, Genes, chromosomes & cancer.

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

T. Haferlach, S. Schnittger, W. Kern, 2009, Leukemia.

Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure

C Haferlach, M Dugas, A Kohlmann, 2011, Leukemia.

lymphocytic leukemia cells lacking functional p53 CD154 induces p73 to overcome the resistance to apoptosis of chronic

T. Kipps, A. Kater, Jean Y. J. Wang, 2013 .

CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

T. Kipps, A. Kater, Jean Y. J. Wang, 2006, Blood.

Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.

A. Kohlmann, T. Haferlach, S. Schnittger, 2005, Journal of the National Cancer Institute.

Comment on: coagulopathy following Crotaline snakebites in northeast Florida.

M. Mullins, F. Dicker, 2023, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Blood Cancer Journal.

International external quality assurance of JAK2 V617F quantification

Niels Pallisgaard, Beatriz Bellosillo, Dina Naguib, 2018, Annals of Hematology.

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

T. Haferlach, J. Sundermann, S. Schnittger, 2010, Leukemia.

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Leukemia.

A novel hierarchical prognostic model of AML solely based on molecular mutations.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Blood.

Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations

T. Haferlach, W. Kern, C. Haferlach, 2016, Leukemia.

Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia

T. Haferlach, W. Kern, C. Haferlach, 2017, Leukemia.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia

Christoph Schmid, Torsten Haferlach, Wolfgang Kern, 2016, Haematologica.

Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia

N. Schmitz, S. Schnittger, W. Kern, 2015 .

Quantification of rare NPM1 mutation subtypes by digital PCR

T. Haferlach, S. Schnittger, W. Kern, 2014, British journal of haematology.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups

T. Haferlach, S. Schnittger, W. Kern, 2014, Leukemia.

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration

T. Haferlach, W. Kern, C. Haferlach, 2021, Leukemia.

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

T. Haferlach, S. Schnittger, W. Kern, 2008, Leukemia.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Haematologica.

Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome

A. Kohlmann, T. Haferlach, S. Schnittger, 2013 .

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib

C. Bokemeyer, J. Dierlamm, M. Binder, 2019, Tumori.

Trisomy 13 Defines a Subgroup of Myeloid Malignancies with an Extremely High Frequency of AML1 Gene Mutations and Newly Defined VEGFR-1 Mutations.

T. Haferlach, S. Schnittger, C. Schoch, 2006 .

Correlation of Flow Cytometrically Determined Expression of ZAP-70 Using Two Different Antibodies with IgVH Mutation Status and Cytogenetics in 539 Patients with Chronic Lymphocytic Leukemia.

T. Haferlach, S. Schnittger, C. Schoch, 2006 .

First European JAK2-V617f interlaboratory quality control study carried out by the MPN&MPNR-Euronet (COST ACTION BM0902)

Niels Pallisgaard, Hans Carl Hasselbach, A. Cassinat, 2014 .

AML classification in the year 2023: How to avoid a Babylonian confusion of languages

T. Haferlach, W. Kern, C. Haferlach, 2023, Leukemia.

Evidence of clonality in cases of hypereosinophilia of undetermined significance

T. Haferlach, C. Vetro, W. Kern, 2019, Leukemia & lymphoma.

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms

T. Haferlach, J. Sundermann, S. Schnittger, 2011, Leukemia.

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern

T. Haferlach, W. Kern, C. Haferlach, 2019, Leukemia.

SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias

B. Johansson, T. Fioretos, T. Haferlach, 2008, Leukemia.

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML

T. Haferlach, S. Schnittger, W. Kern, 2010, Genes, chromosomes & cancer.

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Haematologica.

Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia

T. Haferlach, W. Kern, C. Haferlach, 2015 .